Xtrackers MSCI USA Climate Action Equity ETF(USCA.US)

Company Encyclopedia
View More
name
Xtrackers MSCI USA Climate Action Equity ETF
USCA.US
News
View More

REG - JPMorgan Japanese IT - Transaction in Own Shares

JPMorgan Japanese Investment Trust PLC announced the repurchase of 100,000 Ordinary Shares into Treasury at a price of 711.00 pence per share. Following this transaction, the Company holds a total of 25,646,985 shares in Treasury, with 158,966,203 shares remaining in issue. The Company will only re-issue Treasury shares at a premium to net asset value.

London Stock Exchange·
US
JPM
+0.55%
London Stock Exchange·
US
JPM
+0.55%

REG - JPMorgan EM G&I Plc - Transaction in Own Shares

JPMorgan Emerging Markets Growth & Income Plc announced the repurchase of 250,000 Ordinary shares at 143.54 pence per share, bringing the total shares held in Treasury to 352,132,170. The total shares in issue, excluding Treasury shares, is 971,503,080. The Company will only re-issue Treasury shares at a premium to net asset value.

London Stock Exchange·
US
JPM
+0.55%
London Stock Exchange·
US
JPM
+0.55%

Auto File: BYD nabs Tesla’s crown

BYD has overtaken Tesla as the world's largest EV maker, marking a significant shift in the auto industry. Tesla's sales fell nearly 9% in 2025, primarily due to a lack of new models, while BYD's electric car sales grew by 28%. The competition is intensifying as traditional automakers strive to launch more affordable EVs amidst increasing pressure from Chinese rivals. Meanwhile, the self-driving car sector is regaining investor interest, with new advancements showcased at CES. Despite tariffs and economic uncertainty, U.S. car sales rose by 2% in 2025, defying expectations.

Reuters·
US
TSLA
-4.97%
Reuters·
US
TSLA
-4.97%

Nimbus, Lilly sign deal to develop new oral obesity drug

Nimbus Therapeutics has signed a multi-year research and licensing agreement with Eli Lilly to develop AI-driven oral treatments for obesity and metabolic diseases. The deal includes $55 million in upfront payments and up to $1.3 billion in milestones, plus royalties on sales if approved. This collaboration aims to create alternatives to existing weight-loss injections, with a market projected to exceed $150 billion by the early 2030s. Nimbus will leverage its AI technology, while Lilly will provide expertise in metabolic diseases.

Reuters·
US
LLY
+1.82%
Reuters·
US
LLY
+1.82%

Amazon and AUMOVIO Partner to Advance Autonomous Vehicle Development

Amazon.com Inc. has partnered with AUMOVIO, designating AWS as AUMOVIO’s preferred cloud provider for autonomous vehicle development. This collaboration aims to enhance the development of safer self-driving vehicles by utilizing AWS’s cloud infrastructure and AI capabilities alongside AUMOVIO’s automotive expertise, focusing on innovation, efficiency, and safety in the autonomous mobility sector.

Reuters·
US
AMZN
+3.81%
Reuters·
US
AMZN
+3.81%
© 2026 Longbridge｜Disclaimer